» Articles » PMID: 33390598

The Effect of Prednisone on Histologic and Gross Characteristics in Canine Mast Cell Tumors

Overview
Journal Can Vet J
Date 2021 Jan 4
PMID 33390598
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of the study was to determine whether neoadjuvant prednisone therapy affects histological features of cutaneous and subcutaneous mast cell tumors. Twenty-eight dogs with a treatment naïve > 1-cm diameter mast cell tumor (MCT) were randomly assigned (Random number generator; Random.org, Dublin, Ireland) in a blinded fashion to receive either prednisone or placebo (Quality Food Center Pharmacy, Kirkland, Washington, USA). Volumes of mast cell tumors were calculated before incisional and excisional biopsies. Following incisional biopsy, patients received either prednisone (1 mg/kg body weight) daily or a placebo for 7 to 14 days leading up to excisional biopsy. Tumor grade for cutaneous MCT, and mitotic count and atypia for all tumors were reported. Perioperative treatment with prednisone had no significant effect on tumor grade, atypia, or mitotic count. Tumor volume was significantly decreased with prednisone treatment. The use of neoadjuvant prednisone to decrease MCT volume in order to facilitate tumor excision, can be considered without significant concern for change of tumor histologic features in the common population of low- to intermediate-grade MCT.

Citing Articles

Prognostic significance of YKL-40 expression in canine cutaneous mast cell tumors.

Kuo C, Huang W, Yang S, Chang Y, Chang H, Jeng C BMC Vet Res. 2024; 20(1):537.

PMID: 39614259 PMC: 11605933. DOI: 10.1186/s12917-024-04385-1.


Tumor Grade and Mitotic Count Are Prognostic for Dogs with Cutaneous Mast Cell Tumors Treated with Surgery and Adjuvant or Neoadjuvant Vinblastine Chemotherapy.

Anderson K, Pellin M, Snyder E, Clarke D Vet Sci. 2024; 11(8).

PMID: 39195818 PMC: 11360381. DOI: 10.3390/vetsci11080363.


Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.

Brown G, Finlay J, Straw R, Ziea J, Leung B, OConnell K Front Vet Sci. 2022; 9:1003165.

PMID: 36387404 PMC: 9643212. DOI: 10.3389/fvets.2022.1003165.


Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Klahn S, Dervisis N, Lahmers K, Benitez M Vet Sci. 2022; 9(6).

PMID: 35737330 PMC: 9227510. DOI: 10.3390/vetsci9060277.


Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

De Nardi A, Horta R, Fonseca-Alves C, Noleto de Paiva F, Linhares L, Firmo B Cells. 2022; 11(4).

PMID: 35203268 PMC: 8870669. DOI: 10.3390/cells11040618.

References
1.
Abadie J, Amardeilh M, Delverdier M . Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J Am Vet Med Assoc. 2003; 215(11):1629-34. View

2.
Patnaik A, Ehler W, MacEwen E . Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984; 21(5):469-74. DOI: 10.1177/030098588402100503. View

3.
Dos Santos Horta R, Eunice Lavalle G, Narducci Monteiro L, Alves Dos Reis F, de Padua Costa M, Giuliano A . Evaluation of Histological, Immunohistochemical, Clinical and Genetic Prognostic Factors Associated with the Response of Canine Mast Cell Tumours to Glucocorticotherapy. J Comp Pathol. 2018; 165:72-81. DOI: 10.1016/j.jcpa.2018.10.001. View

4.
Weisse C, Shofer F, Sorenmo K . Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc. 2002; 38(1):71-3. DOI: 10.5326/0380071. View

5.
Bostock D, Crocker J, Harris K, Smith P . Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer. 1989; 59(6):915-8. PMC: 2246742. DOI: 10.1038/bjc.1989.193. View